Page 136 - Demo

Chapter 513462. Luijten MAJ, van Litsenburg RRL, Terwee CB, Grootenhuis MA, Haverman L. Psychometric properties of the Patient-Reported Outcomes Measurement Information System (PROMIS®) pediatric item bank peer relationships in the Dutch general population. Qual Life Res. 2021;30(7). 63. Fries JF, Witter J, Rose M, Cella D, Khanna D, Morgan-DeWitt E. Item response theory, computerized adaptive testing, and promis: Assessment of physical function. J Rheumatol. 2014;41(1). 64. Gaasterland CMW, Van Der Weide MCJ, Roes KCB, Van Der Lee JH. Goal attainment scaling as an outcome measure in rare disease trials: A conceptual proposal for validation. BMC Med Res Methodol. 2019. 65. Müller AR, Zinkstok JR, Rommelse NNJ, van de Ven PM, Roes KCB, Wijburg FA, et al. Methylphenidate for attention-deficit/hyperactivity disorder in patients with Smith–Magenis syndrome: protocol for a series of N-of-1 trials. Orphanet J Rare Dis. 2021;16(1). 66. Gaasterland CMW, Jansen-van der Weide MC, Vroom E, Leeson-Beevers K, Kaatee M, Kaczmarek R, et al. The POWER-tool: Recommendations for involving patient representatives in choosing relevant outcome measures during rare disease clinical trial design. Health Policy (New York). 2018. 67. Crossnohere NL, Brundage M, Calvert MJ, King M, Reeve BB, Thorner E, et al. International guidance on the selection of patient-reported outcome measures in clinical trials: a review. Vol. 30, Quality of Life Research. 2021. 68. Pogrow S. How Effect Size (Practical Significance) Misleads Clinical Practice: The Case for Switching to Practical Benefit to Assess Applied Research Findings. Am Stat. 2019;73(sup1). 69. Morel T, Cano SJ. Measuring what matters to rare disease patients - Reflections on the work by the IRDiRC taskforce on patient-centered outcome measures. Orphanet J Rare Dis. 2017;12(1). 70. Matts ST, Webber CM, Bocell FD, Caldwell B, Chen AL, Tarver ME. Inclusion of patient-reported outcome instruments in US FDA medical device marketing authorizations. J Patient-Reported Outcomes. 2022;6(1). 71. US Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures Use in Medical Product Development to Support Labeling Claims. Clinical/Medical Federal Register. 2009. 72. Calvert M, King M, Mercieca-Bebber R, Aiyegbusi O, Kyte D, Slade A, et al. SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. BMJ Open. 2021;11(6). Annelieke Muller sHL.indd 134 14-11-2023 09:07